Prevention of Thromboembolism with Use of Recombinant Hirudin. Results of a Double-Blind, Multicenter Trial Comparing the Efficacy of Desirudin (Revasc) with That of Unfractionated Heparin in Patients Having a Total Hip Replacement*

Avaliação da tromboflebite jugular experimental em equinos tratados com heparina

“…As hirudinas recombinantes (lepirudina e desirudina), que também se ligam irreversivelmente à trombina, mostraram-se superiores à heparina e às HBPM na profilaxia de trombose venosa profunda em cirurgias ortopédicas [34] e no tratamento de doença venosa tromboembólica [33,35]. A limitação para o uso desses medicamentos está no custo elevado [33].…”

New anticoagulants

“…59 Hirudin is cleared via the kidneys so its dose must be adjusted in patients with renal insufficiency. 60 Although hirudin has been evaluated in acute coronary syndromes [61][62][63][64][65][66][67][68][69][70] and for prevention and treatment of DVT, [71][72][73] its development for these indications is no longer being pursued. For acute coronary indications hirudin was marginally more effective than heparin but caused more bleeding (Table 5).…”

Emerging Anticoagulant Drugs

“…[92][93][94] However, it is unlikely that hirudin will ever be approved for acute coronary syndromes because of its narrow therapeutic window and concerns about the risk of bleeding. 79 -81,86,94 Although hirudin was more effective than heparin 95 or LMWH 96 when used for thromboprophylaxis after hip arthroplasty, clinical development of hirudin for venous thromboprophylaxis has not been pursued.…”